BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:40 PM
 | 
Feb 18, 2010
 |  BC Extra  |  Clinical News

VEGF Trap-Eye meets Phase II endpoint

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Bayer AG (Xetra:BAY) reported data from the Phase II DA VINCI trial of VEGF Trap-Eye to treat diabetic macular edema (DME). All four doses of intravitreal...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >